• STAT Plus: Pharmalittle: Novartis to cut 2,500 jobs over four years; fewer price hikes on drugs, but increases outpace cuts

    2 monthes ago - By STAT

    Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a steady downpour dousing the Pharmalot campus. The premises are rather quiet, now that the short people have left for their destinations - the local schoolhouse and gainful employment, to be specific. And the official mascots are snoozing in various corners. This leaves us to fire up the coffee kettle and rummage for interesting items. On that note, here are some tidbits to brighten your day. Hope all goes well and, of course, do keep us in mind when you learn something fascinating...
    Novartis will...
    Read more ...

     

  • Pivotal drug clinical trials a lot cheaper to run than commonly thought, study finds

    Pivotal drug clinical trials a lot cheaper to run than commonly thought, study finds

    2 monthes ago - By MedCity News

    Amid the drug pricing debate, the findings show that trials can be run at relatively low cost and still generate high-quality data, the study's lead author said.
    Read more ...

     

  • STAT Plus: Insulin prices could be much lower and drug makers would still make healthy profits

    2 monthes ago - By STAT

    As prices for diabetes treatments continue to roil consumers, a new study suggests that manufacturers could make both human and analog insulins at low costs and still pocket a profit.
    After analyzing expenses for ingredients, production, and delivery, among other things, the researchers contend that the price for a year's supply of human insulin could be $48 to $71 a person and between $78 and $133 for analog insulins, which are genetically altered forms that are known as rapid or long-acting treatments. Examples of analog insulins include Humalog, Lantus and Novolog. Continue to STAT Plus...
    Read more ...